- Public Comps
- Fangzhou
Fangzhou Valuation Multiples
Discover Fangzhou's revenue and EBITDA valuation multiples and investment history, alongside public comparables like Bike24, Daiichi Co, Jade Group, SRP Groupe and more.
Fangzhou Overview
About Fangzhou
Fangzhou Inc is a online chronic disease management platform in China. It has focus on chronic disease management to address the needs of patients with chronic diseases, such as hypertension, cardiovascular and respiratory chronic diseases. The company provide comprehensive medical services and online retail pharmacy services through Jianke Platform. The principal segment of the group are online retail pharmacy services, comprehensive medical services, Wholesale and customized content and marketing solutions. Key revenue is generated from Online retail pharmacy services.
Founded
2019
HQ

Employees
488
Website
Financials (LTM)
EV
$67M
Valuation Multiples
Start free trialFangzhou Financials
Fangzhou reported last 12-month revenue of $615M and EBITDA of $4M.
In the same LTM period, Fangzhou generated $94M in gross profit, $4M in EBITDA, and $2M in net income.
Revenue (LTM)
Fangzhou P&L
In the most recent fiscal year, Fangzhou reported revenue of $525M and EBITDA of $5M.
Fangzhou is profitable as of last fiscal year, with gross margin of 16%, EBITDA margin of 1%, and net margin of 0%.
Financial data powered by Morningstar, Inc.
Fangzhou Stock Performance
Fangzhou has current market cap of $125M, and enterprise value of $67M.
Market Cap Evolution
Fangzhou's stock price is $0.09.
Fangzhou share price decreased by 83.4% in the last year.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $67M | $125M | 2.9% | - | 4.5% | -83.4% | $0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialFangzhou Valuation Multiples
Fangzhou trades at 0.1x EV/Revenue multiple, and 18.3x EV/EBITDA.
EV / Revenue (LTM)
Fangzhou Financial Valuation Multiples
As of September 1, 2026, Fangzhou has market cap of $125M and EV of $67M.
Fangzhou has a P/E ratio of 80.1x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Fangzhou Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Fangzhou Margins & Growth Rates
Fangzhou grew revenue by 27% and EBITDA by 100% in the last fiscal year.
In the most recent fiscal year, Fangzhou reported gross margin of 16%, EBITDA margin of 1%, and net margin of 0%.
Fangzhou Margins
Fangzhou Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Fangzhou Operational KPIs
Fangzhou's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.2M for the same period.
Fangzhou's Rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fangzhou's Rule of X is 68% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Fangzhou Competitors
Fangzhou competitors include Bike24, Daiichi Co, Jade Group, SRP Groupe, Komplett, Global Fashion Group, Autoserver Co, Nelly Group, Medifast and a.k.a. Brands.
Most Fangzhou public comparables operate across Consumer E-commerce, Pharmacies, Vertical E-commerce and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.4x | 0.4x | 7.5x | 6.6x | |||
| 0.2x | 0.2x | 4.6x | - | |||
| 0.9x | 0.9x | 5.7x | - | |||
| 0.2x | 0.2x | (8.1x) | (4.9x) | |||
| 0.2x | 0.2x | (15.1x) | 4.9x | |||
| 0.1x | 0.1x | (24.0x) | 3.0x | |||
| 1.4x | 1.4x | 3.3x | - | |||
| 0.8x | 0.8x | 4.9x | 5.6x | |||
This data is available for Pro users. Sign up to see all Fangzhou competitors and their valuation data. Start Free Trial | ||||||
Fangzhou VC Funding History
Before going public, Fangzhou raised $281M in total equity funding, across 4 rounds.
Last private valuation of Fangzhou was $600M, after raising $130M in September 2018 from ShenZhen GTJA Investment Group, Crescent Point, and HBM Healthcare Investments.
Fangzhou Funding Rounds
Investments by Fangzhou
Fangzhou has invested in 1 company to date.
Latest investment by Fangzhou was on May 21st 2019. Fangzhou invested in Biofourmis in their $35M Series B round (EV/Revenue multiple available to Pro users).
Latest Investments by Fangzhou
| Description | Biofourmis is a Boston-headquartered digital therapeutics company founded in 2015. It creates AI-driven software platforms combining biosensors and machine learning to personalize care for heart failure, COPD, and cancer patients. Biofourmis delivers remote monitoring tools to clinicians and cost-saving analytics to payers in the United States, Singapore, and India. The firm collaborates with hospitals like Mass General Brigham on large-scale deployments predicting clinical deteriorations for early interventions. |
| HQ Country | |
| HQ City | Boston, MA |
| Deal Date | 21 May 2019 |
| Round | Series B |
| Raised | $35M |
| Investors | SGInnovate; MMV Europe & Asia-Pacific; Openspace Capital; Fangzhou; EDBI; Aviva Ventures; Peak XV Partners |
| Valuation | $250M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Fangzhou investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Fangzhou
| When was Fangzhou founded? | Fangzhou was founded in 2019. |
| Where is Fangzhou headquartered? | Fangzhou is headquartered in China. |
| How many employees does Fangzhou have? | As of today, Fangzhou has over 488 employees. |
| Who is the CEO of Fangzhou? | Fangzhou's CEO is Fangmin Xie. |
| Is Fangzhou publicly listed? | Yes, Fangzhou is a public company listed on HKEX. |
| What is the stock symbol of Fangzhou? | Fangzhou trades under 06086 ticker. |
| When did Fangzhou go public? | Fangzhou went public in 2024. |
| Who are competitors of Fangzhou? | Fangzhou main competitors include Bike24, Daiichi Co, Jade Group, SRP Groupe, Komplett, Global Fashion Group, Autoserver Co, Nelly Group, Medifast, a.k.a. Brands. |
| What is the current market cap of Fangzhou? | Fangzhou's current market cap is $125M. |
| What is the current revenue of Fangzhou? | Fangzhou's last 12 months revenue is $615M. |
| What is the current revenue growth of Fangzhou? | Fangzhou revenue growth (NTM/LTM) is 35%. |
| What is the current EV/Revenue multiple of Fangzhou? | Current revenue multiple of Fangzhou is 0.1x. |
| What is the current EBITDA of Fangzhou? | Fangzhou's last 12 months EBITDA is $4M. |
| What is Fangzhou's EBITDA margin? | Fangzhou's last 12 months EBITDA margin is 1%. |
| What is the current EV/EBITDA multiple of Fangzhou? | Current EBITDA multiple of Fangzhou is 18.3x. |
| How many companies Fangzhou has acquired to date? | Fangzhou hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Fangzhou has invested to date? | As of September 2026, Fangzhou has invested in 1 company. |
| In what companies Fangzhou invested in? | Fangzhou invested in Biofourmis. |
See public comps similar to Fangzhou
Lists including Fangzhou
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.





